This morning there's a plethora of stuff to blog about: the Takeda-Millennium deal, more commentary about Merck and Schering-Plough and the extent of the Vytorin/Zetia fallout, Genentech's biotech bellweather earnings after the closing bell today, just to name a few.
Pfizer and Nektar Therapeutics said Wednesday clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to end talks with potential partners to market the product.
Shares of Wyeth and Elan surged Monday on the promise of a new Alzheimer's drug. Can you trade it?
Last night while on the elliptical and watching "NBC Nightly News," one spot amid the wall-to-wall commercials for drugs caught my attention. It looks like after 10 years since the first erectile dysfunction pill came on the market--Pfizer's Viagra celebrated a decade since winning FDA approval last week--the makers of Levitra are trying a new marketing tack.
I don't know how I missed this one, but the Wall Street Journal's Health Blog didn't forget that this week that Pfizer and, perhaps, some men and women are celebrating the tenth birthday of Viagra. So, happy birthday little blue pill.
Ahead of the weekend, CNBC asks the experts where investors should place their bets.
The pharmaceutical sector faces the looming "patent cliff" -- but Credit Suisse's Catherine Arnold finds lots of opportunities in the sector for the careful investor.
The American College Of Cardiology kicks off its annual meeting in Chicago on Saturday. What’s the trade ahead of this major meeting of heart doctors?
As proxy statements pop up on www.sec.gov, investors can get a peek at who's making what. When you go to the web site, click on "Search for company filings," then click on "Companies and other filers," enter the ticker symbol, click on "Find companies" and then open up the "14A" or proxy statement.
Merck this morning announced that it has filed for Food and Drug Administration approval of its blockbuster cervical cancer vaccine, Gardasil, for women 27-45 years old. Right now it's approved for females 9-26.
Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.
First, Pfizer gave up on its inhaled insulin Exubera, then NovoNordisk threw in the towel and now it looks like Lilly is going to bow out. Alkermes, which is working on a palm-sized product called, "AIR Insulin," put out a press release today saying it expects its partner on the device, Lilly, to decide next week that it will exit the deal. ALKS shares hit a new low on the news.
Stocks are tumbling. Bonds yields are falling faster than Hillary Clinton's poll numbers. And fears are growing that the commodities bubble could burst. What to do?
The economy's worsening. So's inflation. And the stock market is tanking. What to do? CNBC asked market experts for their best investment advice. Here are some of their picks.
There's nearly $3.5 trillion dollars waiting to be invested in the markets, according to Frederic Dickson, chief market strategist of D.A. Davidson. So what's keeping it out? And what should investors do in the meantime?
U.S. regulators have rejected a long-acting injectable form of Eli Lilly and Co's blockbuster schizophrenia drug Zyprexa, the company said Thursday, sending its shares down almost 2 percent.
When Schering-Plough Chairman and CEO Fred Hassan recently decided to buy another $2 million worth of SGP shares in the wake of the Vytorin study takedown, the company put out a press release.
Healthcare spending is expected to nearly double to $4.3 trillion by 2017. Who’s most likely to benefit and can you trade it?
According to The Center for Responsive Politics' web site Pfizer Chairman and CEO Jeff Kindler has opened his wallet again for Sen. Hillary Clinton. You can see his latest "give" here. Twice now within the past year Kindler has given the maximum amount ($2,300) an individual can contribute to a candidate.
A top industry insider gives us the dish on a story of the week. Get the details now!